Cynthia Lynch, MD

Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.

In the context of recently approved novel regimens, expert Cynthia Lynch, MD, revisits the optimal sequencing of therapy for patients with HER2+ metastatic breast cancer.

Data from the HER2CLIMB, NALA, and SOPHIA trials that led to the FDA approval of respective agents in the setting of HER2+ metastatic breast cancer.

Focusing on real-world treatment selection, Cynthia Lynch, MD, considers how the DESTINY-Breast03 trial impacted her practice and broader treatment guidelines.

Insight on the safety events observed in the DESTINY-Breast03 trial and how this translates to real-world adverse event management in HER2+ metastatic breast cancer.

Expert perspectives on the DESTINY-Breast03 trial, which compared T-DXd to T-DM1 in the setting of relapsed/refractory HER2+ metastatic breast cancer.

Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.